ACADIA Pharmaceuticals Inc. (ACAD) Reaches $27.86 After 5.00% Up Move, Compugen Ltd. (USA) (CGEN) Had 4 Bulls

June 19, 2017 - By Hazel Jackson

The stock of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is a huge mover today! About 214,161 shares traded. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) has declined 15.19% since June 19, 2016 and is downtrending. It has underperformed by 31.89% the S&P500.The move comes after 9 months positive chart setup for the $3.51 billion company. It was reported on Jun, 19 by Barchart.com. We have $29.25 PT which if reached, will make NASDAQ:ACAD worth $175.50M more.

Among 5 analysts covering Compugen (NASDAQ:CGEN), 4 have Buy rating, 0 Sell and 1 Hold. Therefore 80% are positive. Compugen had 8 analyst reports since August 5, 2015 according to SRatingsIntel. FBR Capital initiated Compugen Ltd. (USA) (NASDAQ:CGEN) rating on Thursday, October 15. FBR Capital has “Outperform” rating and $14.0 target. The rating was upgraded by Zacks on Wednesday, September 2 to “Hold”. The stock of Compugen Ltd. (USA) (NASDAQ:CGEN) has “Buy” rating given on Wednesday, August 5 by MLV. On Wednesday, March 9 the stock rating was maintained by JMP Securities with “Market Outperform”. The rating was maintained by Oppenheimer with “Buy” on Wednesday, August 5. The firm earned “Sell” rating on Friday, August 21 by Zacks. Cowen & Co initiated Compugen Ltd. (USA) (NASDAQ:CGEN) on Thursday, October 15 with “Outperform” rating. See Compugen Ltd. (USA) (NASDAQ:CGEN) latest ratings:

Compugen Ltd. is a therapeutic discovery company. The company has market cap of $190.20 million. The Firm focuses on infrastructure to discover drug targets and develop therapeutics. It currently has negative earnings. The Firm is engaged in the research, development and commercialization of therapeutic and product candidates.

About 26,373 shares traded. Compugen Ltd. (USA) (NASDAQ:CGEN) has declined 29.94% since June 19, 2016 and is downtrending. It has underperformed by 46.64% the S&P500.

ACADIA Pharmaceuticals Inc. is a biopharmaceutical company. The company has market cap of $3.51 billion. The Firm is focused on the development and commercialization of medicines for central nervous system disorders. It currently has negative earnings. The Company’s lead drug candidate, NUPLAZID (pimavanserin), is used for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis (PD Psychosis).

Among 8 analysts covering ACADIA Pharmaceuticals (NASDAQ:ACAD), 5 have Buy rating, 0 Sell and 3 Hold. Therefore 63% are positive. ACADIA Pharmaceuticals had 17 analyst reports since August 7, 2015 according to SRatingsIntel. The stock of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) earned “Buy” rating by JP Morgan on Friday, September 4. Piper Jaffray upgraded ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) rating on Thursday, August 27. Piper Jaffray has “Neutral” rating and $48.0 target. The firm has “Buy” rating by Bank of America given on Tuesday, November 8. The stock of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) has “Buy” rating given on Friday, August 7 by Needham. Leerink Swann initiated ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) on Tuesday, October 4 with “Mkt Perform” rating. The company was upgraded on Friday, January 22 by Piper Jaffray. Piper Jaffray downgraded the shares of ACAD in report on Friday, August 7 to “Neutral” rating. The stock of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) has “Overweight” rating given on Friday, August 7 by Piper Jaffray. The company was maintained on Sunday, August 9 by Cowen & Co. The rating was initiated by Goldman Sachs with “Neutral” on Friday, November 11.

Since December 27, 2016, it had 0 insider buys, and 5 insider sales for $9.01 million activity. On Tuesday, February 14 the insider Baity Glenn sold $1.05 million. On Tuesday, February 21 Moore Terrence O sold $311,490 worth of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) or 7,856 shares.

Investors sentiment decreased to 1.06 in 2016 Q4. Its down 0.14, from 1.2 in 2016Q3. It dropped, as 42 investors sold ACADIA Pharmaceuticals Inc. shares while 58 reduced holdings. 31 funds opened positions while 75 raised stakes. 119.51 million shares or 2.68% more from 116.39 million shares in 2016Q3 were reported. Point72 Asset L P invested 0.25% in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD). Goldman Sachs Group reported 1.54M shares stake. The Illinois-based North Star Invest Management has invested 0% in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD). Point72 Asia (Hong Kong) Limited accumulated 1,223 shares or 0.03% of the stock. Fiera Capital Corporation owns 160,704 shares. Ellington Mngmt Gp Limited Com has 0.08% invested in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD). Envestnet Asset Management reported 0% stake. Moreover, Ray Gerald L And has 0.75% invested in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) for 180,280 shares. Finemark National Bank & Trust And has 200 shares. Rhenman Asset Mngmt Ab reported 0.39% in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD). Jefferies Group Limited Liability has invested 0% in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD). Morgan Stanley reported 191,984 shares. California-based National Planning has invested 0.08% in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD). Northern Tru has 0% invested in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) for 462,466 shares. California State Teachers Retirement Systems reported 198,660 shares.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.